Literature DB >> 9430646

Nucleo-cytoplasmic shuttling of the hdm2 oncoprotein regulates the levels of the p53 protein via a pathway used by the human immunodeficiency virus rev protein.

J Roth1, M Dobbelstein, D A Freedman, T Shenk, A J Levine.   

Abstract

The hdm2 gene is overexpressed in a variety of human tumors. Its gene product localizes predominantly to the nucleus, where it acts as an inhibitor of the p53 tumor suppressor gene product. It is shown here that the hdm2 oncoprotein constantly shuttles between the nucleus and the cytoplasm. Shuttling of hdm2 does not depend on its interaction with p53. Nuclear export of hdm2 is mediated by a signal sequence similar to the nuclear export signal of the rev protein from human immunodeficiency virus and other lentiviruses. Mutation of this signal sequence abolishes detectable nucleo-cytoplasmic shuttling. When fused to a carrier protein, the hdm2 signal sequence can mediate nuclear export after intranuclear microinjection into HeLa cells. The export of hdm2 can be blocked by a competitive inhibitor of rev export, arguing that the export pathways for hdm2 and rev are either overlapping or identical. Inhibition of its export modifies the ability of hdm2 to block p53-mediated transcriptional activation, and hdm2's export function is required to accelerate the degradation of p53. Thus the rev nuclear export pathway may be used to regulate an oncogene product's activity and modulate cellular growth.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9430646      PMCID: PMC1170405          DOI: 10.1093/emboj/17.2.554

Source DB:  PubMed          Journal:  EMBO J        ISSN: 0261-4189            Impact factor:   11.598


  90 in total

1.  The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation.

Authors:  J Momand; G P Zambetti; D C Olson; D George; A J Levine
Journal:  Cell       Date:  1992-06-26       Impact factor: 41.582

2.  The p53-mdm-2 autoregulatory feedback loop.

Authors:  X Wu; J H Bayle; D Olson; A J Levine
Journal:  Genes Dev       Date:  1993-07       Impact factor: 11.361

3.  Amplification of a gene encoding a p53-associated protein in human sarcomas.

Authors:  J D Oliner; K W Kinzler; P S Meltzer; D L George; B Vogelstein
Journal:  Nature       Date:  1992-07-02       Impact factor: 49.962

4.  Two distinct mechanisms alter p53 in breast cancer: mutation and nuclear exclusion.

Authors:  U M Moll; G Riou; A J Levine
Journal:  Proc Natl Acad Sci U S A       Date:  1992-08-01       Impact factor: 11.205

5.  Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53.

Authors:  J D Oliner; J A Pietenpol; S Thiagalingam; J Gyuris; K W Kinzler; B Vogelstein
Journal:  Nature       Date:  1993-04-29       Impact factor: 49.962

6.  p53 Mutation and MDM2 amplification in human soft tissue sarcomas.

Authors:  F S Leach; T Tokino; P Meltzer; M Burrell; J D Oliner; S Smith; D E Hill; D Sidransky; K W Kinzler; B Vogelstein
Journal:  Cancer Res       Date:  1993-05-15       Impact factor: 12.701

7.  MDM2 gene amplification in metastatic osteosarcoma.

Authors:  M Ladanyi; C Cha; R Lewis; S C Jhanwar; A G Huvos; J H Healey
Journal:  Cancer Res       Date:  1993-01-01       Impact factor: 12.701

8.  The mdm-2 oncogene can overcome wild-type p53 suppression of transformed cell growth.

Authors:  C A Finlay
Journal:  Mol Cell Biol       Date:  1993-01       Impact factor: 4.272

9.  The DNA-dependent protein kinase: requirement for DNA ends and association with Ku antigen.

Authors:  T M Gottlieb; S P Jackson
Journal:  Cell       Date:  1993-01-15       Impact factor: 41.582

10.  Amplification and overexpression of the MDM2 gene in a subset of human malignant gliomas without p53 mutations.

Authors:  G Reifenberger; L Liu; K Ichimura; E E Schmidt; V P Collins
Journal:  Cancer Res       Date:  1993-06-15       Impact factor: 12.701

View more
  190 in total

Review 1.  Are there multiple proteolytic pathways contributing to c-Fos, c-Jun and p53 protein degradation in vivo?

Authors:  C Salvat; C Aquaviva; I Jariel-Encontre; P Ferrara; M Pariat; A M Steff; S Carillo; M Piechaczyk
Journal:  Mol Biol Rep       Date:  1999-04       Impact factor: 2.316

Review 2.  Control of NF-kappa B transcriptional activation by signal induced proteolysis of I kappa B alpha.

Authors:  R T Hay; L Vuillard; J M Desterro; M S Rodriguez
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  1999-09-29       Impact factor: 6.237

3.  Phosphorylation of Ser-20 mediates stabilization of human p53 in response to DNA damage.

Authors:  N H Chehab; A Malikzay; E S Stavridi; T D Halazonetis
Journal:  Proc Natl Acad Sci U S A       Date:  1999-11-23       Impact factor: 11.205

Review 4.  Molecular interaction map of the mammalian cell cycle control and DNA repair systems.

Authors:  K W Kohn
Journal:  Mol Biol Cell       Date:  1999-08       Impact factor: 4.138

5.  Stress signals utilize multiple pathways to stabilize p53.

Authors:  M Ashcroft; Y Taya; K H Vousden
Journal:  Mol Cell Biol       Date:  2000-05       Impact factor: 4.272

6.  MdmX protects p53 from Mdm2-mediated degradation.

Authors:  M W Jackson; S J Berberich
Journal:  Mol Cell Biol       Date:  2000-02       Impact factor: 4.272

7.  Discrete domains mediate the light-responsive nuclear and cytoplasmic localization of Arabidopsis COP1.

Authors:  M G Stacey; S N Hicks; A G von Arnim
Journal:  Plant Cell       Date:  1999-03       Impact factor: 11.277

8.  A leucine-rich nuclear export signal in the p53 tetramerization domain: regulation of subcellular localization and p53 activity by NES masking.

Authors:  J M Stommel; N D Marchenko; G S Jimenez; U M Moll; T J Hope; G M Wahl
Journal:  EMBO J       Date:  1999-03-15       Impact factor: 11.598

Review 9.  Mdm2: the ups and downs.

Authors:  T Juven-Gershon; M Oren
Journal:  Mol Med       Date:  1999-02       Impact factor: 6.354

10.  The tumour suppressor protein p53 can repress transcription of cyclin B.

Authors:  K Krause; M Wasner; W Reinhard; U Haugwitz; C L Dohna; J Mössner; K Engeland
Journal:  Nucleic Acids Res       Date:  2000-11-15       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.